NCT06044311View on ClinicalTrials.gov

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

June 1, 2027

Conditions
Adenocarcinoma EsophagusLocally Advanced AdenocarcinomaSiewert Type I Adenocarcinoma of Esophagogastric JunctionSiewert Type II Adenocarcinoma of Esophagogastric Junction
Interventions
DRUG

Vactosertib

200 mg orally, twice daily for five days a week, for 2 weeks and again for 4 weeks after chemoradiotherapy.

DRUG

Standard of Care Chemotherapy

Neoadjuvant chemotherapy treatment as per standard of care.

RADIATION

Concurrent Radiation

Neoadjuvant radiation treatment as per standard of care.

Trial Locations (1)

44106

RECRUITING

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Sakti Chakrabarti

OTHER